Pharmacologic Management of Psychosis in the Elderly: A Critical Review

Journal of Geriatric Psychiatry and Neurology

Volumn 16, Issue 4, 2003, Pages 213-218

  Hoeh, Nicholas R ^a   Gyulai, Laszlo ^a   Weintraub, Daniel ^a   Streim, Joel ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Elderly; Geriatric; Psychosis; Psychotropic; Review

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TRAZODONE; VALPROATE SEMISODIUM;

ALZHEIMER DISEASE; BIPOLAR DISORDER; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR DEPRESSION; METHODOLOGY; MOOD DISORDER; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCORING SYSTEM; SENESCENCE; SYMPTOM;

AGED; ALZHEIMER DISEASE; BENZODIAZEPINES; BIPOLAR DISORDER; CLOZAPINE; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; PIRENZEPINE; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 0345303860     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/0891988703258663     Document Type: Review

References (60)

1. Targum SD, Abbott JL. Psychoses in the elderly: a spectrum of disorders. J Clin Psychiatry 1999; 60:4-10.
2. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry 1998; 59:5-12.
3. Östling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatry 2002; 59:53-59.
4. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000; 8:29-34.
5. Tariot PN, Ismail MS. Use of quetiapine in elderly patients. J Clin Psychiatry 2002; 13:21-26.
6. Palmer BW, McClure FS, Jeste DV. Schizophrenia in late life: findings challenge traditional concepts. Harv Rev Psychiatry 2001; 9:51-58.
7. Sajatovic M, Perez D, Brescan D, Ramirez LF. Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacol Bull 1998; 34:819-823.
8. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000; 13:28-32.
9. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Risperidone Working Group. Int J Geriatr Psychiatry 2000; 15:506-514.
10. Jeste DV, McClure FS. Psychoses: diagnosis and treatment in the elderly. New Dir Mental Health Serv 1997; 53-70.
11. Sajatovic M, Ramirez LF, Garver D, et al. Clozapine therapy for older veterans. Psychiatr Serv 1998; 49:340-344.
12. Kiraly SJ, Gibson RE, Ancill RJ, Holliday SG. Risperidone: treatment response in adult and geriatric patients. Int J Psychiatry Med 1998; 28:255-263.
13. Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12:11-18.
14. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999; 7:132-138.
15. Meyers BS, Alexopoulos GS, Kakuma T, et al. Decreased dopamine beta-hydroxylase activity in unipolar geriatric delusional depression. Biol Psychiatry 1999; 45:448-452.
16. Schatzberg AF, Rothschild AJ. Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149:733-745.
17. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999; 60:116-118.
18. Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13:23-28.
19. O'Connor MK, Knapp R, Husain M, et al. The influence of age on the response of major depression to electroconvulsive therapy: a C.O.R.E. report. Am J Geriatr Psychiatry 2001; 9:382-390.
20. Chen ST, Altshuler LL, Melnyk KA, et al. Efficacy of lithium vs. valproate in the treatment of mania in the elderly: a retrospective study. J Clin Psychiatry 1999; 60:181-186.
21. Colenda CC. Mania in late life. The challenges of treating older adults. Geriatrics 2002; 57:50, 53-54.
22. Sajatovic M. Treatment of bipolar disorder in older adults. Int J Geriatr Psychiatry 2002; 17:865-873.
23. McDonald WM. Epidemiology, etiology, and treatment of geriatric mania. J Clin Psychiatry 2000; 61:3-11.
24. Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptoms in Parkinson's disease patients with dementia. J Am Geriatr Soc 1996; 44:296-299.
25. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227-2229.
26. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999; 56:595-601.
27. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000; 107:59-71.
28. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Move Disord 2000; 15:201-211.
29. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002; 52:438-445.
30. Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Move Disord 2002; 17:1031-1035.
31. Marsh L, Lyketsos C, Reich SG. Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia. Psychosomatics 2001; 42:477-481.
32. Fabbrini G, Barbanti P, Aurilia C, et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23:41-43.
33. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002; 25:107-110.
34. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002; 18:258-264.
35. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Move Disord 2001; 16:1171-1174.
36. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br Med J 1992; 305:673-678.
37. McKeith IG, Fairbairn AF, Bothwell RA, et al. An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 1994; 44:872-877.
38. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124.
39. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatry 1999; 14:459-466.
40. Cummings JL, Street J, Masterman D, Clark WS. Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 13:67-73.
41. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry 2000; 15:280-281.
42. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031-2036.
43. Gormley N, Rizwan MR. Prevalence and clinical correlates of psychotic symptoms in Alzheimer's disease. Int J Geriatr Psychiatry 1998; 13:410-414.
44. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989; 146:577-587.
45. Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer's disease: prevalence and clinical correlates. Int J Geriatr Psychiatry 2000; 15:99-107.
46. Forstl H, Burns A, Levy R, Cairns N. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry 1994; 165:53-59.
47. Levy ML, Cummings JL, Fairbanks LA, et al. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease. Biol Psychiatry 1999; 45:422-425.
48. Rapoport MJ, van Reekum R, Freedman M, et al. Relationship of psychosis to aggression, apathy and function in dementia. Int J Geriatr Psychiatry 2001; 16:123-130.
49. Kennedy JS, Zagar A, Bymaster F, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16:S24-S32.
50. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16:39-44.
51. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998; 155:1512-1520.
52. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60:107-115.
53. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946-955.
54. Brodaty H, Ames D, Snowdon J, et al. A randomised placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003; 64:134-143.
55. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57:968-976.
56. Street JS, Clark WS, Kadam DL, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia. Int J Geriatr Psychiatry 2001; 16:S62-S70.
57. Mintzer J, Madhusoodanan S, Brenner R. Risperidone in dementia. Psychiatric Ann 2000; 30:181-187.
58. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22:1068-1084.
59. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002; 159:460-465.
60. Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc 2001; 49:1294-1300.